New cell therapy tested in kids with aggressive leukemia
NCT ID NCT04678336
Summary
This early-phase study tested a new cell therapy called CART123 in children and young adults (ages 1-29) whose acute myeloid leukemia (AML) had returned or did not respond to standard treatments. Doctors collected and genetically modified the patient's own immune cells (T cells) to target and attack leukemia cells. The main goal was to find a safe dose and understand the side effects of this experimental treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.